Company Spotlight: SafeBeat Rx App - AI for QT Intervals and Drug Dosing

We unpack the FDA 510(k) summary for the SafeBeat Rx App, a software tool that uses machine learning to measure ECG intervals and suggest antiarrhythmic drug dosing. We discuss its clinical testing demographics, its performance against standard databases, and the specific limitations placed on its home monitoring workflow.

Key points

• The SafeBeat Rx App is a Software as a Medical Device (SaMD) cleared to analyze ECGs and provide provisional interval measurements like QT, QTc, and QRS.
• It includes an optional non-device function that suggests dosing for specific antiarrhythmic drugs like sotalol and dofetilide, based on the manufacturer's drug label.
• The FDA clearance relied on a primary predicate device (CardioLogs ECG Analysis Platform) and a reference device (AliveCor QT Service) to justify the use of machine learning for QT calculations.
• Clinical validation used a retrospective dataset with a mean age of 40.9 years, but had notable gaps in demographic data, including 16.5% unknown race or ethnicity and 36.2% unknown BMI.
• The FDA explicitly warns that the software workflow intended for professional healthcare environments should not be used in the home environment to adjust QT prolonging medications.

Source: FDA 510(k) summary K251218: SafeBeat Rx App (SafeBeat Rx) - U.S. Food and Drug Administration, 2026

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: SafeBeat Rx (safebeatrx.com) · Product: SafeBeat Rx App · FDA 510(k) K251218

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-safebeat-rx-app-ai-for-qt-intervals-and-drug-dosing-8e8f83